

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING APPLICATION UNDER 37 CFR 53(b)
WITHOUT FILING FEE OR EXECUTED INVENTOR'S DECLARATION

Assistant Commissioner for Patents 388 U.S. PTO Atty. Dkt. 2801-14
Washington, DC 20231

Date: March 22, 2000

Sir:

This is a request for filing a new PATENT APPLICATION under Rule 53(b) entitled:

2-AMINOTETRALINES, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS, FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES without a filing fee and/or without an executed inventor's oath/declaration.

This application is made by the below identified inventor(s). Attached hereto are the following papers:

- ☒ An abstract together with
62 pages of specification and claims including
7 numbered claims and also attached is/are
sheets of accompanying drawings.
- ☒ This application is based on the following prior foreign application(s):

Application No.	Country	Filing Date
RM97A000568	Italy	22 September 1997
PCT/IT98/00252	Italy	22 September 1998

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

- ☐ This application is based on the following prior provisional application(s):

Application No.	Filing Date
-----------------	-------------

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

☐ Certified copy/ies of foreign applications attached.

This application is a ☐ continuation/☐ division/☐ continuation-in-part of application Serial No. , filed

Please amend the specification by inserting before the first line: --This application is a ☐ continuation/☐ division/☐ continuation-in-part of application Serial No. , filed , the entire content of which is hereby incorporated by reference in this application.--

☒ Please amend the specification by inserting before the first line: --This is a continuation of PCT application No. PCT/IT98/00252, filed 22 September 1998, the entire content of which is hereby incorporated by reference in this application.--

☐ Please amend the specification by inserting before the first line: --This application claims the benefit of U.S. Provisional Application No. , filed , the entire content of which is hereby incorporated by reference in this application.--

☒ Preliminary amendment to claims (attached hereto), to be entered before calculation of the fee.

☒ Also attached. PTO-1449 w/ International Search Report

Inventor:	Nicola	FANTO	Italian
	(first)	(last)	(citizenship)
Residence: (city)	Roma	(state/country)	Italy
Post Office Address:	Viale Pico della Mirandola, 50, Roma, Italy		
(Zip Code)	I-00142		
2. Inventor:	Gian	P. MORETTI	Italian
	(first)	(last)	(citizenship)
Residence: (city)	Roma	(state/country)	Italy
Post Office Address:	Via Marco Valerio Corvo, 58, Roma, Italy		
(Zip Code)	I-00174		

NOTE: FOR ADDITIONAL INVENTORS, check box ☒ and attach sheet with same information.

Address all future communications to NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
ARC:pdcc

NIXON & VANDERHYE P.C.

By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: _____

3. Inventor: Piero FORESTA Italian
(first) MI (last) (citizenship)
Residence: (city) Pomezia (state/country) Italy
Post Office Address: Via L. Sturzo, 46, Pomezia, Italy
(Zip Code) I-00040

Address all future communications to NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

FANTO et al.

Atty. Ref.: 2801-14

Serial No. (To be assigned)

Group:

Filed: March 22, 2000

Examiner:

For: 2-AMINOTETRALINES, A PROCESS FOR
THEIR PREPARATION, AND
PHARMACEUTICAL COMPOSITIONS, FOR
THE PREVENTION AND THERAPEUTIC
TREATMENT OF INFLAMMATORY
AND/OR AUTOIMMUNE PATHOLOGIES

* * * * *

March 22, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

In order to place the above-identified application in better condition for
examination, please amend the application as follows:

IN THE CLAIMS

Claim 5, line 5, delete ", 2 or 3".

FANTO et al.
Serial No. (To be assigned)

REMARKS

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Richard R. Crawford 22770 (for)

Arthur R. Crawford

Reg. No. 25,327

ARC:pdc
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**2-Aminotetralines, a process for their preparation, and
pharmaceutical compositions, for the prevention and
therapeutic treatment of inflammatory and/or autoimmune
pathologies.**

5 The invention described herein relates to derivatives of 2-aminotetralines and their pharmacologically acceptable salts, a process for their preparation, pharmaceutical compositions suitable for prophylactic and therapeutic treatment of septic shock, and for the treatment of inflammatory and/or autoimmune
10 pathologies which will be better defined here below, in which the aetiopathogenetic role of inflammatory cytokines is well established.

6,7-Substituted-2-aminotetralines which are active in the treatment of septic shock are well known.

15 EP-A-0 730 861, which is incorporated herein for reference purposes, describes a class of such 6,7-substituted-2-aminotetralines and particularly the compound (R,S)-2-amino-6-fluoro-7-methoxytetraline (hereinafter referred to as ST 626).

The inflammatory and/or autoimmune pathologies to be
20 treated with the compositions according to the invention described herein are, for example, rheumatoid arthritis, pancreatitis, inflammatory bowel disease, systemic lupus erythematosus, glomerulonephritis and encephalomyelitis.

./.

Hereinafter, reference will be made only to septic shock, it being understood that the other pathologies due to inflammatory cytokines can also be effectively treated according to the invention.

Septic shock is an extremely severe clinical syndrome which
5 may set in as a result of infections mainly caused either by gram-negative or gram-positive bacteria, by protozoa or by viruses, and characterised by leukocytosis, fever, tachycardia, hypotension and renal, respiratory, cardiac and hepatic insufficiency.

It should be stressed, however, that the severity of septic
10 shock is independent of the type of micro-organism responsible for the syndrome (Parrillo J.E., Pathogenetic mechanisms of septic shock. *New Engl. J. Med.*, **328**:1471-1477, 1993) but is related to the extent of the individual inflammatory response to the antigen responsible for the toxic insult.

15 Despite the significant improvement in antibiotic therapy and in intervention protocols in intensive care units, over the past few years, shock remains one of the major causes of morbidity and mortality in hospitalised patients. It is estimated that in the USA it is responsible for approximately 100,000 deaths/year (Glauser
20 M.P., Zanetti G., Baumgartner J.D., Cohen J., Septic shock: pathogenesis. *Lancet*, **338**:732-736, 1991).


The most decisive and characteristic feature of septic shock is the body's reaction to products deriving from lysis or from microbial metabolism.

The first of these substances to be identified and the one
5 most used in experimental research is lipopolysaccharide (LPS); a constituent of the gram-negative bacteria wall, chemically consisting in a polysaccharide portion which varies according to the bacterial species, and a lipid portion (lipid A) which is constant, and present in the blood of septicaemic subjects in the
10 form of micelles. If administered to animals, LPS is capable of reproducing all the cardiocirculatory and neurological symptoms encountered in shock (Olson. N.C., Salzer W.L., McCall C.E., Biochemical, physiological and clinical aspects of endotoxaemia. *Molec. Aspects Med.*, 10: 511-629, 1988). It is therefore identifiable
15 as the prime mover in the chain of events which leads to the triggering of the clinical symptoms via activation of the intrinsic and extrinsic pathways of the coagulative cascade and the secretion of cytokines of mainly macrophage-monocyte origin, such as, for instance TNF, IL-1 and INF- γ (Bone R.C., A critical
20 evaluation of new agents for the treatment of sepsis. *J. Am. Med. Ass.*, **266**: 1686-1691, 1991).


The increasing importance this syndrome has come to take on over the past few years, its severity and the inadequate therapeutic means currently available make the rapid discovery of therapeutic agents capable of effectively combating the progression of the disease a highly desirable goal.

It has now been found that a new class of 6,7-substituted 2-aminotetralines exhibits potent activity in the prevention and therapeutic treatment of the above-mentioned pathologies.

2-Aminotetraline derivatives according to the invention can occur both as free bases with general formula (I):



and as pharmacologically acceptable salts with general formula (II):



wherein:

R and R₁, are independently, halogen, particularly fluorine; hydroxy; C1-C4 alkoxy, particularly methoxy, optionally substituted in position ω with groups OH, NH₂, NR₃R₄, where R₃

5 and R₄ are independently H, C1-C4 alkyl, unsubstituted or substituted in position ω with groups OH, NH₂;

C1-C4 alkanoyl, particularly acetyl;

C1-C4 alkyl; carbamoyl; carbamoyloxy; amino; amino substituted NR₃R₄, where R₃ and R₄ have the above-mentioned meanings;

10 R₂ is hydrogen; halogen, particularly fluorine; hydroxy; methoxy, with the proviso that the case is excluded in which the 2-aminotetraline is a raceme in which (a) R=R₁=CH₃O; OH; R₂=H; or (b) R=F; R₁=CH₃O; OH; R₂=H; and

X⁻ is the monovalent anion of a pharmacologically acceptable
15 acid.

What is meant by pharmacological acceptable salts of compounds of formula (II) are any of its salts with an acid that does not give rise to unwanted toxic or side effects. Such acids are well known to pharmacologists and to experts in pharmacy and
20 pharmaceutical technology.

Examples of such salts - though not exclusively these - are chloride, bromide, orotate, acid aspartate, acid citrate, acid


phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.


FDA approved salts are listed in *Int. J. of Pharm.* 33 (1986),
5 201-217, which is incorporated herein for reference purposes.

Preferred examples of specific compounds as per the invention described herein are:

- S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride (ST 1237);
R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride (ST 1238);
10 (R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride
(ST 1269);
(R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride (ST 1275);
(R,S)-2-amino-7-fluoro-6-hydroxytetraline hydrochloride (ST
1267);
15 (R,S)-7-acetyl-2-amino-6-methyltetraline hydrochloride (ST 1274);
(R,S)-2-amino-7-fluoro-6-methoxytetraline hydrochloride (ST
1262).

The process for preparing the compounds according to the invention described herein either as free bases or as
20 pharmacologically acceptable salts is reported in the following
reaction schemes:

REACTION SCHEME 1

REACTION SCHEME 2

With reference to the above reaction schemes, the following examples, wherein $X=Cl^-$, illustrate the invention without limiting it exclusively to these.

5 **EXAMPLE 1 (scheme 1)**

Preparation of S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride (ST 1237) 8a

a) Preparation of S(-)-trifluoroacetyl-aspartic anhydride 1a

L-Aspartic acid (100 g; 0.75 moles) was suspended in
10 trifluoroacetic acid (300 mL), the resulting suspension was kept under stirring and cooled to $-20^{\circ}C$ in an ice/salt bath. Trifluoroacetic anhydride (300 mL; 2.16 moles) was slowly added thereto under stirring. At the end of the addition the resulting mixture was cautiously refluxed at $45^{\circ}C$ overnight.

15 When the reaction ended, the solution was brought to dryness in an evaporator and the solid residue was washed three times with hexane under stirring, each time removing the hexane by decantation; the residue was again completely brought to dryness. Finally, the residue was triturated under stirring with
20 hexane-ethyl ether, the resulting mixture was filtered and the residue was dried under vacuum. 150 g of compound 1a were obtained (yield 95%).

M.P.: 140-142°C

$[\alpha]_D = -40.7$ (c = 1% methyl alcohol)

$^1\text{H-NMR}(\text{DMSO-d}_6)$, Varian 300 MHz, $\delta(\text{p.p.m.})$: 2,85-3,3 (2H,m, CH_2); 4,95-5,1(1H,m, CHNH); 9,6-9,8 (1H,bd, CHNHCOCF_3).

5 **b) Preparation of S(+)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-(N-trifluoro-acetyl)-aminobutanoic acid 3a**

S(-)-trifluoroacetyl-aspartic anhydride (150 g; 0.712 moles) was suspended in 2-fluoroanisole (300 mL; 2.67 moles), the resulting mixture was vigorously stirred and then anhydrous
10 aluminium chloride (240 g; 1.57 moles) was slowly added in small portions. When the addition was completed, the mixture was kept under vigorous stirring at 40-45°C for 24 h.

Anhydrous CH_2Cl_2 and a further 60 g of AlCl_3 were added and the reaction mixture was kept under stirring for a further 48 h.

15 The solid residue was then treated with one litre of CH_2Cl_2 by grinding it under stirring. The methylene chloride containing the excess fluoroanisole was separated. The solid residue was filtered off and added portionwise to 2 litres of 6 M HCl kept under vigorous stirring. On completing the addition, the mixture was
20 kept under stirring for 30 min. The acid phase was then repeatedly extracted with ethyl ether. The combined ether phases were washed with water, dried over anhydrous sodium sulphate

and then brought to dryness. A raw solid residue was obtained which was crystallised by 1:1 AcOEt/hexane. 188 g of compound 3a were obtained (yield 78 %).

M.P.: 113-115°C

5 $[\alpha]_D = + 27.5$ (c = 1% methyl alcohol)

$^1\text{H-NMR}(\text{CD}_3\text{OD})$, Varian 300 MHz, $\delta(\text{p.p.m.})$: 3,6 (2H,m, CH_2NH);

3,96(3H,S, PhOCH_3); 4,88-5,01 (1H,m, CH_2CHNH);

7,18-7,22 (1H,t,Ar); 7,7-7,8(1H,dd,Ar); 7,82-7,9(1H,bd,Ar).

c) Preparation of S(+)-4-(3-fluoro-4-methoxyphenyl)-2-(N-trifluoro-
10 acetyl)-aminobutanoic acid 4a

Compound 3a (100 g; 0.297 moles) was dissolved in trifluoro-acetic acid (500 mL). The resulting solution was cooled to 0°C and triethylsilane (300 mL; 1.89 moles) slowly added. When the addition was complete, the mixture was slowly brought to its
15 boiling point and kept at boiling temperature for 4 h.

The mixture was then brought to complete dryness in an evaporator; the residue was washed twice with ethyl ether, each time bringing the mixture to dryness to completely eliminate the trifluoroacetic acid. The oily residue thus obtained was cooled to
20 -20°C in an ice/salt bath and then treated under stirring with an NaHCO_3 saturated solution whose pH had been adjusted to 10 with 4N NaOH.

The final alkaline phase was cautiously acidified to pH 3 with 6N HCl, at 0°C. A precipitate was obtained which was repeatedly extracted with CH₂Cl₂. The combined organic extracts were washed in a small amount of water, dried over anhydrous Na₂SO₄ and brought to dryness. The oily residue was dissolved in a small amount of ethyl acetate and precipitated with hexane under stirring. The mixture was kept under stirring overnight, filtered and the residue was dried. 72 g of compound 4a were obtained (yield 75%).

10 M.P.: 113-115°C

[α]_D = + 11.3 (c = 1% methyl alcohol) analysis: conforms to standards.

¹H-NMR(CDCl₃), Varian 300 MHz, δ(p.p.m.):

2,0-2,18 (1H,m,CHHCHNH); 2,22-2,36 (1H,m,CHHCHNH);

15 2,6-2,7(2H,t,PhCH₂CH₂); 3,84(3H,S,PhOCH₃);

4,6-4,7(1H,m,CH₂CHNH); 6,78(1H,bd,CHNHCOCF₃);

6,8-6,92(2H,m,Ar).

d) Preparation of S(-)-2-(N-trifluoroacetyl)amino-6-fluoro-7-methoxy-1-tetralone 5a

20 Compound 4a (70 g; 0.217 moles) was dissolved in anhydrous methylene chloride (1400 mL). The resulting mixture was cooled to 0°C in an ice bath and then phosphorus

pentachloride (70 g; 0.336 moles) was slowly added. At the end of the addition, the mixture was kept under stirring at 0°C for about 2 h, and then cooled to -20°C. Aluminium chloride (56 g; 0.42 moles) was added to the mixture in small portions.

5 Following the addition, the mixture was kept for 2 h at room temperature and then cautiously heated to boiling point and kept at boiling temperature for about 6 h.

The mixture was then cooled to 0°C and crushed ice (about 300 mL) was added portionwise under stirring to destroy the
10 excess reactants. The mixture was extracted three times with CH₂Cl₂. The combined organic phases were dried over anhydrous Na₂SO₄ and brought to dryness. A yellowish solid was obtained which was dissolved in a small volume of ethyl acetate and then precipitated with hexane. 40 g of compound 5a were obtained
15 (yield 60%).

M.P.: 184-185°C

[α]_D = - 55.4 (c = 1% methyl alcohol)

¹H-NMR (CDCl₃), Varian 300 MHz, (p.p.m.):

1,83-2,2 (1H,m,CHHCHNH); 2,8-2,88 (1H,m,CHHCHNH);

20 2,9-3,0 (1H,mCHHCH₂); 3,15-2,26 (1H,m,CHHCH₂);

3,92(3H,s,PhOCH₃); 4,53-4,62 (1H,m,CH₂CHNHCOCF₃);

6,88 (1H,d,Ar.); 7,57 (1H,d,Ar.); 7,43 (1H,bs,CHNHCOCF₃).

e) Preparation of S(-)-2-(N-trifluoroacetyl)amino-6-fluoro-7-methoxy-tetraline 6a

Compound 5a (40 g; 0.131 moles) was suspended in boron
etherate trifluoride (340 mL) at 0°C. Triethylsilane (90 mL; 0.567
5 moles) was added to the suspension at 0°C, and the suspension
was kept under stirring for 4 days at room temperature. At the
end of the reaction a saturated solution of NaHCO₃ (pH 8-9) was
added to the reaction mixture and the aqueous phase was
extracted four times with CH₂Cl₂. The combined organic phases
10 were washed with water, dried over anhydrous Na₂SO₄, filtered
and brought to dryness.

The raw compound thus obtained was recrystallised from
isopropyl ether. 30 g of compound 6a were obtained (yield 78 %).

M.P.: 45-47°C

15 $[\alpha]_D = -80$ (c = 1% methyl alcohol)

¹H-NMR(CDCl₃), Varian 300 MHz, δ (p.p.m.):

1,78-1,9 (1H,m,CHHCNNH); 2,0-2,15 (1H,m,CHHCHNH);

2,6-2,72 (1H,dd,PhCHHCHNH);

2,73-2,9 (2H,m,PhCHHCHNH,PhCHHCH₂);

20 3,03-3,15 (1H,dd,PhCHHCH₂) 4,2-4,35 (1H,m,CHNH);

6,38 (1H,bd,CHNHCOCF₃); 6,6 (1H,d,Ar); 6,8 (1H,d,Ar).

f) Preparation of S(-)-2-amino-6-fluoro-7-methoxytetraline hydrochloride 7a

Compound 6a (30 g; 0.13 moles) was dissolved in methanol (225 mL) and water (225 mL) containing K₂CO₃ (54 g; 0.391
5 moles).

The resulting solution was refluxed under stirring for 3 hours.

Methanol was removed under vacuum and a further 100 mL of water added to the solution.

The aqueous phase was repeatedly extracted with CH₂Cl₂.
10 The combined organic phases were dried over anhydrous Na₂SO₄, filtered and brought to dryness. The oily solid thus obtained was dissolved in ethyl ether acidified with HCl (15% solution in ethanol) and the solid precipitate was filtered off and redissolved in methanol, decoloured with activated charcoal, filtered,
15 concentrated under vacuum and finally crystallised with n-propanol.

Crystallisation was repeated twice giving 12.6 g of compound 7 (Yield 53%).

M.P.: 263-265 °C

20 $[\alpha]_D = -52.5$ (c = 1% H₂O)

¹H -NMR (CDCl₃), Varian 300 MHz, δ ppm):

1,6-1,8 (1H, m, CHHCHN+); 2,0-2,15 (1H,,m, CHHCHN+);

2,6-2,75 (3H,m,PhCH \underline{H} HCHN $\underline{+}$, PhCH \underline{H}_2 CH $\underline{2}$);

2,95-3.05 (1H,DD,PhCHH \underline{H} CHN $\underline{+}$); 3,45-3,55 1H, m, CHN $\underline{+}$);

6,7-6,7(2H,m,Ar).

g) Preparation of S(-)-2-amino-6-fluoro-7-hydroxytetraline hydro-
chloride (ST 1237) 8a

A solution of S(-)-2-amino-6-fluoro-7-methoxytetraline hydro-chloride 7a (3 g; 0.13 moles) in 20 mL of hydrobromic acid (47% aqueous solution) was kept at reflux temperature overnight. At the end of refluxing the solution was concentrated and brought to dryness under vacuum. The residue thus obtained was repeatedly washed under stirring with acetone and filtered off, redissolved in a 1:1 water/methanol mixture and eluted through a column containing 60 mL of Amberlyst A 21 resin, activated in basic form.

The eluate was acidified with 2 N hydrochloric acid and then concentrated to dryness under vacuum; the residue thus obtained was washed with acetone, filtered off and again dissolved in 1:1 water/methanol and eluted through a column containing 60 mL of Amberlyst A 21 resin activated in acid form.

The eluate was decoloured with activated charcoal, filtered through celite and concentrated in a small volume. Acetone was added thereto obtaining a precipitate that was filtered off and dried in the oven under vacuum.

2.2 g of compound 8a were obtained (yield 78 %).

M.P.: 259-261°C

$[\alpha]_D = -55.4$ (c = 1% H₂O)

¹H-NMR (D₂O), Varian 300 MHz, δ (p.p.m.):

- 5 1.6-1.8 (1H, m, CH₂CH \underline{H} HCHN⁺); 2,0-2,1 (1H, m, CH₂CH \underline{H} HCHN⁺);
2,5-2,7 (3H, m, PhCH \underline{H} CH₂CH₂), PhCH \underline{H} HN⁺); 2.85-3,0 (1H, m,
PhCH \underline{H} HN⁻);
3,4-3,55 (1H, m, CHN⁺); 6,55-6,8 (2H, 2d, Ar.).

EXAMPLE 2 (scheme 1)

10 **Preparation of R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride (ST 1238) 8b**

a) Preparation of R(+)-trifluoroacetyl aspartic 1b

The preparation is basically similar to that utilised for S(-)-trifluoro-acetyl-aspartic 1a using D(-)aspartic acid as the starting
15 product (yield 86%).

M.P.: 142-144°C

$[\alpha]_D = +40.0$ (c = 1% methyl alcohol)

¹H-NMR: in accordance with and coinciding with that obtained with product 1a.

20 **b) Preparation of R(-)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-(N-trifluoroacetyl)aminobutanoic acid 3b**

The preparation is basically similar to that utilised for S(+)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-(N-trifluoroacetyl) aminobutanoic acid 3a, using anhydride 1b as the starting material (yield 57%).

5 M.P.: 86-88°C

$[\alpha]_D = -28.0$ (c = 1% methyl alcohol)

$^1\text{H-NMR}$: in accordance and coinciding with that obtained with product 3a.

10 c) Preparation of R(-)-4-(3-fluoro-4-methoxyphenyl)-2-(N-trifluoroacetyl)aminobutanoic acid 4b

The preparation is basically similar to that utilised for S(+)-4-(3-fluoro-4-methoxyphenyl)-2-(N-trifluoroacetyl)-aminobutanoic acid 4a using acid 3b as the starting material (yield 65%).

M.P.: 110-112 °C

15 $[\alpha]_D = -11.2$ (c = 1% methyl alcohol)

$^1\text{H-NMR}$: in accordance and coinciding with that obtained with product 4a.

d) Preparation of R(+)-2-(N-trifluoroacetyl)amino-6-fluoro-7-methoxy-1-tetralone acid 5b

20 The preparation is basically similar to that utilised for S(-)-2-(N-trifluoroacetyl)-amino-6-fluoro-7-methoxy-1-tetralone acid 5a using anhydride 4b as the starting material (yield 84%).

M.P.: 185-186°C

$[\alpha]_D = +66.0$ (c = 1% methyl alcohol)

$^1\text{H-NMR}$: in accordance and coinciding with that obtained with product 5a.

5 **e) Preparation of R(+)-2-(N-trifluoroacetyl)-amino-6-fluoro-7-methoxytetraline acid 6b**

The preparation is basically similar to that utilised for S(-)-2-(N-trifluoroacetyl)-amino-6-fluoro-7-methoxytetraline acid 6a using tetralone 5b as the starting material (yield 47%).

10 M.P.: 145-147°C

$[\alpha]_D = +92.0$ (c = 1% methyl alcohol)

$^1\text{H-NMR}$: in accordance and coinciding with that obtained with product 6a.

15 **f) Preparation of R(+)-2-amino-6-fluoro-7-methoxytetraline hydrochloride 7b**

The preparation is basically similar to that utilised for S(-)-2-amino-6-fluoro-7-methoxytetraline hydrochloride 7a. using tetraline 6b as the starting material (yield 64%).

M.P.: 260-262°C

20 $[\alpha]_D = +48.5$ (c = 1% H_2O)

$^1\text{H-NMR}$: in accordance and coinciding with that obtained with product 7a.

g) Preparation of R(+)-2-amino-5-fluoro-7-hydroxytetraline hydrochloride (ST 1238) 8b

The preparation is basically similar to that utilised for S(-)-2-amino-5-fluoro-7-hydroxytetraline hydrochloride (ST 1237) 8a using tetraline hydrochloride 7b as the starting material (yield 78%).

M.P.: 260-262°C

$[\alpha]_D = + 55,0$ (c = 1% H₂O)

¹H-NMR (D₂O), Varian 300 MHz, δ (p.p.m.):

10 1,6-1,8(1H,m,CH₂CH \underline{H} CHN⁺); 2,0-2,1 (1H,m,CH₂CH \underline{H} CHN⁺);
2,5-2,7(3H,m,PhCH \underline{H} CH₂CH₂)PhCH \underline{H} CHN⁺);
2,85-3,0(1H, m, PhCH \underline{H} CHN); 3,4-3,55(1H,m,CHN⁺);
6,55-6,8(2H,2d,Ar.).

EXAMPLE 3 (scheme 1)

15 **Preparation of (R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride (ST 1269) 7c**

a) Preparation of (R,S)-trifluoroacetyl-aspartic anhydride 1c

The preparation is basically similar to that utilised for S(-)-trifluoroacetyl-aspartic anhydride 1a using D,L-aspartic acid as the starting product (yield 96%).

M.P.: 133-134°C

¹H-NMR: in accordance and coinciding with that obtained with product 1a.

a') Preparation of 2,3-difluoroanisole 2

20 g (0.154 moles) of 2,3-difluorophenol were salified by shaking the product at room temperature in a solution of 6.24 g of NaOH in 60 mL of water to completely dissolve it.

To the solution cooled to about 10°C, 14.4 mL of dimethyl sulphate, were slowly added; the solution was then heated to reflux temperature and refluxed for 24 h.

The reaction mixture was brought to room temperature and extracted with methylene chloride; the organic phase was washed with water, N sulphuric acid and again with water until a neutral pH was obtained.

The solution was dehydrated with anhydrous sodium sulphate and the solvent removed under vacuum to give 21 g of compound a' as a reddish oil which was analysed by NMR and utilised as it was

(yield 94% on the raw material).

¹H-NMR (D₂O) Varian 300 MHz δ (p.p.m.): 3,9 (3H, S, PhOCH₃);

6,6-7,2 (3H, m, aromatics).

b) Preparation of (R,S)-4-(2,3-difluoro-4-methoxyphenyl)-4-oxo-2(N-trifluoroacetyl)aminobutanoic acid 3c

The preparation is basically similar to that utilised for S(+)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2(N-trifluoroacetyl) aminobutanoic acid 3a using anhydride 1c and 2,3-difluoroanisole as the starting products and 2 and 72 h as the reaction time instead of 48 h (yield 23%).

$^1\text{H-NMR}$ (D_2O) Varian 300 MHz δ (p.p.m.): 3,9 (3H, S, PhOCH_3); 6,6-7,2 (3H, m, aromatics).

c) Preparation of (R,S)-4-(2,3-difluoro-4-methoxyphenyl)-2-(N-trifluoroacetyl)aminobutanoic acid 4c

The preparation is similar to that utilised for S(+)-4-(3-fluoro-4-methoxyphenyl)-2-(N-trifluoroacetyl) aminobutanoic acid 4a using acid 3c as the starting product (yield 76%).

$^1\text{H-NMR}$ (CDCl_3), Varian 300 MHz, δ (p.p.m.):

2,0-2,2 (1H, m, CHHCHN^+) 2,2-2,4 (1H, m, CHHCHCN);

2,6-2,8 (2H, t, PhCH_2CH_2); 3,86 (3H, S, PhOCH_3);

4,6-4,72 (1H, bq, CH_2CHNH) ; 6,6-6,7 (1H, bt, Ar);

6,75-6,88 (2H, m, Ar, CHNHCOCF_3).

d) Preparation of (R,S)-2-(N-trifluoroacetyl)amino-5,6-difluoro-7-methoxy-1-tetralone 5c

The preparation is basically similar to that utilised for S(-)-(N-trifluoroacetyl)amino-6-fluoro-7-methoxy-1-tetralone 5a using acid 4c as the starting product and 3 h at reflux after the addition

of aluminium chloride instead of 6 h as the reaction time (yield 26%).

¹H-NMR (CDCl₃), Varian 300 MHz, δ (p.p.m.):

1,85-2,0 (1H, m, CHHCHN+) 2,84-3,07 (2H,m,CHHNH,
5 PhCHHCH₂);
3,13-3,24 (1H,m,PhCHHCH₂); 3,93 (1H,S,PhOCH₃);
4,55-4,65 (1H,m, CH₂CHNH) ; 7,38-7,42 (1H,dd,Ar);
7,43-(1H,bs,,CHNHCOCF₃).

10 e) Preparation of (R,S)-2-(N-trifluoroacetyl)amino-5,6-difluoro-7-methoxytetraline 6c

The preparation is basically similar to that utilised for S(-)-(N-trifluoroacetyl)amino-6-fluoro-7-methoxytetraline 6a (example 1) using tetralone 5c as the starting product and 7 days instead of 4 as the reaction time (yield 46%).

15 ¹H-NMR (CDCl₃), Varian 300 MHz, δ (p.p.m.):

1,75-1,9 (1H, m, CHHCHN+) 2,04-2,16 (2H,m,CHHCHNH);
2,6-2,9 (3H,m,PhCH₂CHNH, PhCHHCH₂);
3,05-3,15 (1H,dd,PhCHHCH₂); 3,84 (3H,s,PhOCH₃);
4,2-4,33 (1H,m,CHNHCOCF₃); 6,22 (1H,bs,CHNHCOCF₃);
20 6,9-6,94(1H,bd,Ar).

f) Preparation of (R,S)-2-amino-5,6-difluoro-7-methoxy-1-tetraline hydrochloride ST (1269) 7c

The preparation is basically similar to that utilised for S(-)-2-amino-6-fluoro-7-methoxytetraline hydrochloride 7a using tetraline 6c as the starting product and isopropanol as the crystallisation solvent

5 (yield 62%).

M.P.: decomposes at 210 °C

¹H-NMR (D₂O), Varian 300 MHz, δ (p.p.m.):

1,6-1,8(1H, m, CH₂CH_HCHN⁺) 2,0-2,2 (1H,m,CH₂CH_HCHN⁺, 2,5-2,9 (3H,m,PhCH_HCHN⁺,PhCH₂CH₂); 2,9-3,1 (1H,m, PhCHCHN⁺);
10 3,4-3,6 (1H,m,CHN⁺); 6,5-6,6(1H,d,Ar).

EXAMPLE 4 (scheme 1)

Preparation of (R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride (ST 1275) 7d

a) Preparation of (R,S)-trifluoroacetyl aspartic anhydride 1c

15 (See example 3)

b) Preparation of (R,S)-4-(3-fluoro-4-methyl-phenyl)-4-oxo-2-(N-trifluoroacetyl)aminobutanoic acid 3d

The preparation is basically similar to that utilised for S(+)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-(N-trifluoroacetyl) aminobutanoic acid 3a using fluorotoluene as the starting product and
20 72 h instead of 48 h as the reaction time (yield 36%).

$^1\text{H-NMR}$ (CDCl_3) Varian 300 MHz, δ (p.p.m.): 2,15 (3H, d, PhCH_3);
3,35-3,42 (1H,dd, CHHCHNH); 3,5-3,6(1H,dd, CHHCHNH);
4,68-4,76 (1H,m, CH_2CHNH); 6,85-6,95 (1H,t,Ar);
7,55-7,65 (2H,m,Ar); 8,0-8,1(1H,bd, CHNHCOCF_3).

5 **c) Preparation of (R,S)-4-(3-fluoro-4-methyl-phenyl)-2-(N-trifluoroacetyl)aminobutanoic acid 4d**

The preparation is basically similar to that utilised for S(+)-4-(3-fluoro-4-methoxyphenyl)-2-(N-trifluoroacetyl)aminobutanoic acid 4a using acid 3d as the starting product (yield 52%).

10 $^1\text{H-NMR}$ (CDCl_3) Varian 200 MHz, δ (p.p.m.): 2,15 (3H, d, PhCH_3);
2,0-2,4 (2H,dd, CH_2CHNH); 2,5-2,7(2H,t, PhCH_2CH_2);
4,5-4,7 (1H,bq, CH_2CHNH); 6,6-6,7 (1H,m,Ar); 6,75-6,95 (2H,m,Ar);
7,35-7,5(1H,bd, CHNHCOCF_3).

15 **d) Preparation of (R,S)-2-(N-trifluoroacetyl)amino-6-fluoro-7-methyl-1-tetralone 5d**

The preparation is basically similar to that utilised for S(-)-2-(N-trifluoroacetyl)amino-6-fluoro-7-methoxy-1-tetralone 5a using acid 4d as the starting product and 1 h at reflux instead of 2 h at room temperature, and, after the addition of aluminium chloride, 6 h at reflux as the reaction time (yield 80%).

20 $^1\text{H-NMR}$ (CDCl_3) Varian 300 MHz, δ (p.p.m.):

1,83-2,0 (1H, d, CHHCHNH); 2,3-(3H,d, PhCH_3);

2,8-2,9(1H,m,CH \underline{H} CHNH); 2,92-3,03 (1H,m,CH \underline{H} CH \underline{H} CH \underline{H});
 3,13-3,25(1H,m,CH \underline{H} CH \underline{H}); 4,53-4,62 (1H,m,CH \underline{H} CHNHCOCF $\underline{3}$);
 7,2(1H,d,Ar); 7,6(1H,d,Ar); 7,45(1H,bs,CHNH \underline{H} COCF $\underline{3}$).

e) Preparation of (R,S)-2-(N-trifluoroacetyl)amino-6-fluoro-7-
 5 methyl-tetraline 6d

The preparation is analogous to that utilised for S(-)-2-(N-tri-fluoroacetyl)amino-6-fluoro-7-methoxytetraline 6a, using tetralone 5d as the starting product (yield 60%).

$^1\text{H-NMR}$ (CDCl $\underline{3}$) Varian 300 MHz, δ (p.p.m.):

10 1,75-1,9 (1H, m, CH \underline{H} CHNH); 2,0-2,15 (1H,m,CH \underline{H} CHNH);
 2,2(3H,s,PhCH $\underline{3}$); 2,6-2,7 (1H,dd,PhCH \underline{H} CHNH);
 2,7-2,9 (2H,m,PhCH \underline{H} CHNH,PhCH \underline{H} CH $\underline{2}$);
 3,03-3,15(1H,dd,PhCH \underline{H} CH $\underline{2}$) 4,25-4,35 (1H,m,CHNH);
 6,2 (1H,b,s,NHCOCF $\underline{3}$); 6,7(1H,d,Ar); 6,9 (1H,d,Ar).

15 f) Preparation of (R,S)-2-amino-6-fluoro-7-methyltetraline hydro-
chloride (ST 1275) 7d

The preparation is basically similar to that utilised for S(-)-2-amino-6-fluoro-7-methoxytetraline hydrochloride 7a, using tetraline 6d as the starting product (yield 67%).

20 M.P.: decomposes at 230 °C

$^1\text{H-NMR}$ (CD $\underline{3}$ OD) Varian 300 MHz, δ (p.p.m.):

1,7-1,9 (1H, m, CH $\underline{2}$ CH \underline{H} CHN $\underline{+}$); 2,15-2,25 (1H,m,CH $\underline{2}$ CH \underline{H} CHN $\underline{+}$);

2,19(3H,S,PhCH₃); 2,7-2,9 (3H,m,PhCHNH⁺,PhCH₂CH₂);
3,05-3,6(1H,m,PhCHCHN⁺); 3,45-3,6(1H,m,CHNH₃⁺);
6,75-6,8 (1H,d,Ar); 6,95-7,0 (1H,d,Ar).

EXAMPLE 5 (scheme 2)

5 **Preparation of (R,S)-2-amino-6-methoxy-7-fluorotetraline**
hydro-chloride (ST 1262) 6a

a) Preparation of 4-(6-methoxy-7-fluorophenyl)-3-carbomethoxy-
3-butanoic acid 1a

9.4 g (0.061 moles) of 3-fluoro-p-anisaldehyde and 10 g
10 (0.068 moles) of dimethyl succinate were dissolved in 15 mL of
anhydrous methanol. The solution thus obtained was added
dropwise at room temperature to a previously prepared solution of
sodium methoxide 1.66 g (0.073 moles). The reaction mixture was
refluxed for 3 h in a nitrogen atmosphere, then cooled and
15 concentrated at half volume under vacuum.

The solution thus obtained was acidified with 2N HCl,
cooling it in an ice bath, and then diluted with water until
precipitation of the product occurred. The precipitate was filtered
off and dissolved in a saturated solution of sodium hydrogen
20 carbonate. The aqueous solution was repeatedly shaken with ethyl
ether and re-acidified with 2N HCl and cooled in an ice bath.

The product was repeatedly extracted from the aqueous solution, with anhydrous sodium sulphate, and the solvent removed under vacuum obtaining a solid product which was crystallised with an ethyl acetate/n-hexane mixture, brought to
5 dryness to give 5.5 g of acid 1a (yield 33%).

M.P.: 141-144°C

¹H-NMR (CDCl₃), Varian 300 MHz, δ (p.p.m.) : 3,55

(2H,s,CH₂COOH);

3,83 (3H,s,COOCH₃); 3,9(3H,s,PhOCH₃); 6,95-7,2 (3H,m,Ar);

10 7,8 (1H,s,CH=C).

b) Preparation of (R,S)-4-(6-methoxy-7-fluorophenyl)-3-carbo-
methoxybutanoic acid 2a

2 g (0.0075 moles) of 4-(6-methoxy-7-fluorophenyl)-3-carbo-
methoxy-3-butanoic acid were dissolved in 80 mL of ethyl acetate
15 and then hydrogenated in Parr apparatus with 200 mg of
palladium on charcoal at 5.5 p.s.i. hydrogen pressure for 1.5 h.
The solution was filtered through celite and the catalyst and
solvent removed under vacuum to give 1.9 g of oil which
spontaneously crystallise (yield 93%).

20 ¹H-NMR (CDCl₃), Varian 200 MHz, δ (p.p.m.)

2,3-2,45 (1H,m,CHCOOCH₃); 2,5-2,75 (2H, m, CH₂COOH);

2,8-3,1 (2H,m,PhCH₂); 3,6 (3H,s,COOCH₃); 3,8 (3H,s,PhOCH₃);

6,75-6,9(3H,m,Ar)

c) Preparation of (R,S)-6-methoxy-7-fluoro-4-oxo-1,2,3,4-tetrahydro-2-naphthoic acid ethyl ester 3a

5 5.6 g (0.021 moles) of (R,S)-4-(6-methoxy-7-fluorophenyl)-3-carbomethoxy-butanoic acid 2a were dissolved in 100 mL of anhydrous methylene chloride; 5 g (0.024 moles) of phosphorus pentachloride were added, and the temperature was maintained at 0°C for 45 min. The temperature was brought to -10°C and 3.6 g (0.027 moles) of aluminium chloride were added to the solution; 10 the temperature was left to rise to 20°C in 40 min, and then the solution was heated to reflux temperature for 1 h.

The solvent was evaporated under vacuum; 100 mL of cold water were added to the suspension which was extracted 3 times with 150 mL of ethyl acetate; the organic solution was dehydrated 15 over anhydrous sodium sulphate and the solvent removed under vacuum to give 4.3 g of solid product (yield 81%).

¹H-NMR (CDCl₃), Varian 200 MHz, δ (p.p.m.)

2,3-2,45 (1H,m,CHCOOCH₃); 2,5-2,75 (2H, m, CH₂COOH);

2,8-3,1 (2H,m,PhCH₂); 3,6 (3H,s,COOCH₃); 3,8 (3H,s,PhOCH₃);

20 6,75-6,9(3H,m,Ar)

d) Preparation of (R,S)-6-methoxy-7-fluoro-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 4a

6 g (0.024 moles) of the (R,S)-6-methoxy-7-fluoro-4-oxo-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 3a were dissolved in 100 mL of a mixture composed of anhydrous methanol and 50 mL of glacial acetic acid; the solution was placed
5 in a Parr apparatus with 800 mg of palladium over charcoal at 50 p.s.i. hydrogen pressure for 4 h.

The catalyst was filtered off through celite and the solvent removed under vacuum, obtaining 5.5 g of solid product (yield 98%).

10 $^1\text{H-NMR}$ (CDCl_3), Varian 300 MHz, δ (p.p.m.):

1,75-1,9 (1H,m, CHHCHCOOCH_3);

2,1-2,22(1H,m, CHHCHCOOCH_3);

2,6-2,8 (3H,m, $\text{PhCH}_2\text{CHCOOCH}_3$, CHCOOCH_3);

2,9 (2H,d, PhCH_2CH_2); 3,7 (3H,s, COOCH_3); 3,83 (3H,s, PhOCH_3);

15 6,62 (1H,d,Ar); 6,78 (1H,d,Ar).

e) Preparation of (R,S)-6-methoxy-7-fluoro-1,2,3,4-tetrahydro-2-naphthoic acid 5a

5.2 g (0.022 moles) of (R,S)-6-methoxy-7-fluoro-1,2,3,4-tetrahydro-2-naphthoic acid 4a were suspended in a solution
20 composed of 2.2 g of potassium carbonate in 50 mL of 50% aqueous solution of methanol; the resulting solution was refluxed for 1 h.

The methanol was removed under vacuum and the solution diluted with 150 mL of water and washed with ethyl ether; the aqueous solution was acidified with 12 N HCl.

The precipitate thus obtained was filtered off and dried to
5 give 4.8 g of product (yield 97%).

$^1\text{H-NMR}$ (CDCl_3), Varian 300 MHz, δ (p.p.m.):

1,8-1,95 (1H,m, CHHCHCOOCH_3);

2,1-2,25 (1H,m, CHHCHCOOCH_3);

2,65-2,85(3H,m, $\text{PhCH}_2\text{CHCOOCH}_3$, CHCOOCH_3);

10 2,95(2H,d, PhCH_2CH_2); 3,82 (3H,s, PhOCH_3);

6,6(1H,d,Ar);6,8(1H,d,Ar).

f) Preparation of (R,S)-2-amino-6-methoxy-7-fluorotetraline
hydro-chloride (ST 1262) 6a

4.11 g (0.018 moles) of (R,S)-6-methoxy-7-fluoro-1,2,3,4-
15 tetrahydro-2-naphthoic acid 5a were dissolved in 9 mL of thionyl
chloride under a nitrogen atmosphere and the solution was heated
to 60°C for 4 h; toluene was then added and the solution
repeatedly extracted under vacuum.

A green oil was obtained which was dissolved in 12 mL of
20 anhydrous acetone and added dropwise to a solution of sodium
azide 1.75 g (0.024 moles) in 12 mL of water, cooling the reaction
mixture to 0°C.

The mixture was left to react under stirring for 30 min leaving the temperature to rise to 20°C. The mixture was again cooled to 0-5°C and 150 mL of water were added.

The precipitate thus obtained was brought to dryness under vacuum, obtaining 3.9 g of acid azide.

The product thus obtained was dissolved in 12 mL of toluene and heated for 30 min to 100°C; the solvent was removed, obtaining a dense oil to which 10 mL of anhydrous benzyl alcohol were added, whereupon the solution was again heated at 100°C for 6 h.

The solution was cooled to 5°C overnight; the precipitate thus obtained was then filtered off and brought to dryness, obtaining 4.7 g of carbobenzoxy derivative.

The product was placed in 350 mL of anhydrous ethanol and dissolved by heating slightly, and acidified with about 2 mL of concentrated HCl; 500 mg of palladium over charcoal were added and the mixture thus obtained was placed in Parr apparatus and hydrogenated for 5 h at 50 p.s.i. hydrogen pressure.

The catalyst was filtered off over celite and repeatedly washed with heated ethanol; the solvent was removed under vacuum and the solid thus obtained was crystallised with an ethanol/ethyl ether mixture (yield 58%).

M.P.: decomposes at 230 °C

^1H -NMR (DMSO d_6), Varian 300 MHz, δ (p.p.m.):

1,6-1,8 (1H,m,CHHCHN $^+$); 2,0-2,2 (1H,m,CHHCHN $^+$);

2,6-3,0(4H,m,PhCH $_2$ CH $_2$,PhCH $_2$ CHN $^+$); 3,8 (3H,s,OCH $_3$);

5 6,8-7,0(2H,2d,Ar)

EXAMPLE 6 (scheme 2)

g) Preparation of (R,S)-2-amino-6-hydroxy-7-fluorotetraline
hydro-chloride (ST 1267) 7

0.6 g (0.0026 moles) of (R,S)-2-amino-6-methoxy-7-
10 fluorotetraline hydrochloride 6a were suspended in 8 mL of
hydrobromic acid 47% solution in water and then heated to 130°C
overnight.

Water was removed by evaporation under vacuum; the dark
solid thus obtained, dissolved in 50% aqueous solution of
15 methanol, was eluted through a column of 20 mL of A-21 resin
activated in a basic form.

The eluted solution was acidified to pH 2 with 3N
hydrochloric acid, concentrated under vacuum and eluted through
a column of 20 mL of A-21 resin activated in hydrochloride form.

20 The solvent was completely removed under vacuum.

The solid thus obtained was treated with acetone, filtered off and crystallised from methanol by addition of ethyl ether; 350 mg of product were obtained (yield 62%).

M.P.: decomposes at about 200 °C.

5 $^1\text{H-NMR}$, (CD_3OD), Varian 300 MHz, δ (p.p.m.):

1,7-1,9 (1H,m, CHHCHN^+); 2,1-2,3 (1H,m, CHHCHN^+);

2,7-3,1(4H,m, PhCH_2CH_2 ; $\text{PhCH}_2\text{CHN}^+$); 3,4-3,6 (1H,m, CHN^+);

6,6-6,85(2H,2d,Ar).

EXAMPLE 7 (scheme 2)

10 **Preparation of (R,S)-2-amino-6-methyl-7-acetyltetraline hydrochloride (ST 1274) 10**

a) Preparation of 4-(6-methylphenyl)-3-carbomethoxy-3-butanoic acid 1b

The preparation is basically similar to that utilised for 4-(6-methoxy-7-fluorophenyl)-3-carbomethoxy-3-butanoic acid 1a,
15 using p-tolualdehyde as the starting product, 3 h as the reaction time at reflux, and a cyclohexane/ethyl acetate mixture as the crystallisation solvent (yield 27%).

$^1\text{H-NMR}$ (CDCl_3); Varian 200 MHz, δ (p.p.m.): 2,35 (3H,s, PhCH_3);
20 3,58 (2H,s, CH_2COOH); 3,83 (3H,s, COOCH_3); 7,15-7,3 (4H,m, Ar);
7,87 (1H,s, $\text{CH}=\text{C}$).

b) Preparation of 4-(6-methylphenyl)-3-carbomethoxy-3-butanoic acid 2b

The preparation is basically similar to that utilised for 4-(6-methoxy-7-fluorophenyl)-3-carbomethoxy-3-butanoic acid 2a, using acid 1b as the starting product, and 2.5 h as the hydrogenation time (yield 94%).

$^1\text{H-NMR}$ (CDCl_3), Varian 200 MHz, δ (p.p.m.): 2,23 (1H,s, PhCH_3); 2,28-2,45(1H,m, CHCOOCH_3); 2,55-2,75 (2H,m, CH_2COOH); 2,9-3,1 (2H,m, PhCH_2); 3,62 (3H,s, COOCH_3); 6,9-7,1 (4H,m,Ar)

c) Preparation of (R,S)-6-methyl-4-oxo-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 3b

The preparation is basically similar to that utilised for (R,S)-6-methoxy-7-fluoro-4-oxo-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 3a, using acid 2b as the starting product (yield 94%).

$^1\text{H-NMR}$ (CDCl_3), Varian 200 MHz, δ (p.p.m.): 2,35 (3H,s, PhCH_3); 2,7-2,9(2H, m, PhCH_2); 3,1-3,2 (3H,m, PhCOCH_2 , CHCOOCH_3); 3,7 (3H,s, COOCH_3); 7,1-7,35 (2H,m,Ar); 7,8 (1H,s,Ar).

d) Preparation of (R,S)-6-methyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 4b

The preparation is basically similar to that utilised for (R,S)-6-methoxy-7-fluoro-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 4a, using methyl ester 3b as the starting product (yield 94%).

¹H-NMR (CDCl₃), Varian 200 MHz), δ (p.p.m.):

1,7-1,95 (1H,m,CHHCHCOCCl₃); 2,1-2,3 (1H,m, CHHCHCOOCH₃);

2,3 (3H,s,PhCH₃);

2,6-2,85 (3H,m,PhCH₂CHCOOCH₃, CHCOOCH₃);

5 2,9-3,0 (2H,d,PhCH₂CH₂);

3,72 (3H,s,COOCH₃); 6,85-7,1 (3H,m,Ar)

h) Preparation of (R,S)-6-methyl-7-acetyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 8

3.8 g (0.0186 moles) of (R,S)-6-methyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester 4b were dissolved in 30 mL of methylene chloride; 5.2 g of aluminium chloride were added to the solution cooled to 5°C under a nitrogen atmosphere and 1.6 mL of acetyl chloride were added dropwise at the same temperature under stirring.

15 The reaction mixture was left to react at room temperature for 1.5 h, whereupon the mixture was cooled by adding 100 mL of cold water very slowly under stirring. The solution was repeatedly extracted with 100 mL (total volume) of methylene chloride and washed repeatedly with cold water.

20 The organic phase was anhydriified with anhydrous sodium sulphate, and the solvent removed under vacuum obtaining a dark solid, which was dried giving 3.8 g of raw product that was

purified by silica gel column chromatography (50 mL), using n-hexane/ethyl acetate 8:2 as the solvent.

The solvent was removed under vacuum obtaining 1.8 g of product (yield 40%).

5 $^1\text{H-NMR}$ (CDCl_3), Varian 300 MHz, δ (p.p.m.):

1,78-2,0 (1H,m, CHHCHCOCOOCH_3);

2,1-2,3 (1H,m, CHHCHCOCOOCH_3); 2,45 (3H,s, COCH_3);

2,55 (3H,s, PhCH_3);

2,65-2,85 (3H,m, $\text{PhCH}_2\text{CHCOCOOCH}_3$, CHCOCOOCH_3);

10 2,95 (2H,d, PhCH_2CH_2); 6,95 (1H,s,Ar); 7,45 (1H,s,Ar).

i) Preparation of (R,S)-6-methyl-7-acetyl-1,2,3,4-tetrahydro-2-naphthoic acid 9

The preparation is basically similar to that utilised for (R,S)-6-methoxy-7-fluoro-1,2,3,4-tetrahydro-2-naphthoic acid 5, using
15 methyl ester 8 as the starting product, 1.5 h at reflux temperature as the reaction time and n-hexane/ethyl acetate as the crystallisation mixture (yield 82%).

$^1\text{H-NMR}$ (CDCl_3), Varian 300 MHz, δ (p.p.m.):

2,78-2,92 (1H,m, CHHCHCOOH); 2,1-2,25 (1H,m, CHHCHCOOH);

20 2,4 (3H,s, COCH_3); 2,5 (3H,s, PhCH_3);

2,7-2,9 (3H,m, $\text{PhCH}_2\text{CHCOOH}$, CHCOOH);

2,9-3,0 (2H, d, PhCH_2CH_2); 6,9 (1H,s,Ar); 7,4 (1H,s,Ar).

1) Preparation of (R,S)-2-amino-6-methyl-7-acetyltetraline hydrochloride (ST 1274) 10

6.5 g (0.028 moles) of (R,S)-6-methyl-7-acetyl-1,2,3,4-tetrahydro-2-naphthoic acid 9 were suspended in 40 mL of anhydrous acetone; 4.3 mL (0.0307 moles) of triethylamine were slowly added dropwise to the suspension. The solution temperature was brought to -5°C and 2.95 mL (0.0307 moles) of ethyl-chlorophormiate dissolved in 4 mL of acetone were slowly added dropwise.

10 3.65 g (0.056 moles) of sodium azide dissolved in 80 mL of water were added dropwise to the solution maintaining the temperature at 0°C; the mixture thus obtained was kept under stirring at 0°C for 1 h, obtaining a precipitate. After the addition of a further 80 mL of cold water the solution was extracted with 100 mL of toluene and the organic solution dehydrated with anhydrous sodium sulphate.

The solution was added to 30 mL of toluene heated to 100°C, and maintained at 100°C for a further 1.5 hours.

The solvent was removed for evaporation under vacuum obtaining 4.9 g of dense lightly stained oil which was suspended in 50 mL of 8N HCl and heated to 100°C under stirring for 1.5 h.

The solvent was removed for evaporation under vacuum; 100 mL of water were then added and the suspension was brought to pH 10 under stirring with 4 N sodium carbonate cooling in an ice bath.

5 The aqueous solution was divided into smaller amounts and extracted with 120 mL of ethyl ether. The organic phase was dehydrated with anhydrous sodium sulphate and gaseous hydrochloric acid was bubbled into the ether solution thus obtained.

10 The precipitate thereby obtained was filtered off under vacuum and dried in air to give 2.3 g of slightly stained solid that was crystallised with a mixture of ethyl acetate/methanol.

The solid was brought to dryness in the oven to give 2 g of colourless crystalline product (yield 30%).

15 M. P.: 195-197°C with decomposition.

$^1\text{H-NMR}$, (CD_3OD), Varian 300 MHz, δ (p.p.m.):

1.75-1.85 (1H,m, CHHCHN^+); 2,15-2,3 (1H,m, CHHCHN^+);

2,42 (3H,s, CH_3CO); 2,53 (3H,s, CH_3Ph);

2,8-3,0(4H,m, $\text{PhCH}_2\text{CHN}^+$), PhCH_2CH_2); 3,5-3,65 (1H,m, CHN^+);

20 7,05 (1H,s,Ar); 7,6 (1H,s,Ar).

The methodological approach most widely employed for the purposes of assessing the possible protective effect of a substance in septic shock, in pre-clinical investigations, is the use of

./.

experimental models of intoxication with a toxic substance (exo- or endotoxin) injected directly into the laboratory animal or released in massive amounts by the infecting cells with which the animal is inoculated.

5 The description of the following pharmacological tests shows the results obtained with some of the compounds according to the invention, in comparison with the reference compound (R,S)-2-amino-6-fluoro-7-methoxytetraline hydrochloride (ST 626).

As mentioned above, the compound ST626 is an already
10 known compound, which is structurally similar to the compounds of the invention and has a similar pharmacological activity.

These results demonstrate the preventive and therapeutical efficacy of the compounds of the invention, and also provide indications as to the possible mechanisms of action responsible
15 for the favourable pharmacological profile of the compounds, namely a drastic lowering of inflammatory cytokine levels (TNF, IL-1 β , IL-6 and IFN- γ) in the blood.

EVALUATION OF THE EFFECT OF ST 1238, ST 1274 AND ST 1275 IN MURINE MODELS OF SEPTIC SHOCK

20 Male BALB/C mice (C. River) aged approx. 6 weeks were utilised (10 animals per experimental group).

The animals, housed in cages at $22 \pm 2^\circ\text{C}$ and $50 \pm 15\%$ relative humidity with 12 h of light (7 am - 7 pm) and 12 h of darkness (7 pm - 7 am) had unrestricted access to food and drinking water.

5 The substances utilised were: LPS (*Escherichia coli* serotype O26:B6), batch 73570 (Difco), LPS (*Salmonella typhosa*) batch 81H4018 (Sigma), SEB (*Staphylococcus aureus*), batch 144H4024 (Sigma), and D-galactosamine batch 031EE002485 (Merck).

The compounds tested were ST1238, ST 1274 and ST 1275.

10 The compound solution pH was corrected, where necessary, with NaOH 0.1 N (maintaining the solution cold and under stirring) to obtain values no lower than pH 5.5.

Lethality induced by *S. typhosa* LPS

Animals were treated intraperitoneally (i.p.) with *S. typhosa*
15 LPS. Prior to use, the endotoxin was first dissolved in sterile saline and then injected in a volume of 200 μL , at the dose of 27.0 mg/kg, corresponding to about the LD₈₀.

The compounds tested were administered intravenously (i.v.) in a volume of 200 μL of sterile saline at the dose approximately
20 corresponding to 1/10 LD₅₀, 30 min before and again 5 min after the endotoxic challenge (LPS).

Lethality induced by *E. coli* LPS in mice sensitised with D-galactosamine

Animals were sensitised with D-galactosamine (1000 mg/kg, i.p.) and, at the same time, treated with *E. coli* LPS (0.30 mg/kg, i.p.) in a total volume of 200 μ L.

The dose of LPS utilised corresponded approximately to 1/10 LD₅₀ in the animals sensitised with D-galactosamine.

The compounds tested were administered intravenously (i.v.) in a volume of 200 μ L of sterile saline, at the dose approximately corresponding to 1/10 LD₅₀, 30 min before and 5 min after, or 5 and 30 min after the LPS challenge.

Lethality induced by SEB (*Staphylococcus aureus*) in mice sensitised with D-galactosamine

Animals were sensitised with D-galactosamine (1000-1500 mg/kg, i.p.) and, at the same time, treated with the enterotoxin SEB (3 mg/kg, i.p.) in a total volume of 200 μ L. The dose of SEB utilised corresponding to approximately the LD₈₀, was evaluated in a preliminary experiment.

The compounds tested were administered intravenously (i.v.) in a volume of 200 μ L of sterile saline, at the dose approximately corresponding to 1/10 LD₅₀, 30 min before and 5 min after, or 5 min and 30 min after the SEB challenge.

Survival was assessed daily for 10 days in all the experiments, taking note of the day when each animal died.

The statistical significance of the protective effect was evaluated using a one-tailed Fisher's exact test.

5 RESULTS

Lethality induced by *S. typhosa* LPS

In this experimental model of endotoxic shock with *S. typhosa* LPS, the compounds ST 1274 and ST 1275 significantly reduce the lethality when administered pre- and post-challenge
10 (p<0.01 and p< 0.05, respectively) (Table 1).

Tab. 1 Effect of ST 1274 and ST 1275 i.v. administration on the lethality induced in mice by injection of *S. typhosa* LPS.

Pre-/post-challenge treatment schedule (-30 and +5 min).

Treatment (dose)	Dead/Total	Survival increase ^a (%)	P ^b
LPS control	14/20	—	—
ST 626 (6 mg/kg, i.v.)	6/20	+40	<0.05
LPS control	18/20	—	—
ST 1274 (5.5 mg/kg, i.v.)	10/20	+40	<0.01
LPS control	10/10	—	—
ST 1275 (4 mg/kg, i.v.)	6/10	+40	<0.05

15

a = Percentage increase in survival of treated animals compared to LPS control.

b = Statistical significance evaluated by one-tailed Fisher's exact test.

Lethality induced by *E. coli* LPS in mice sensitised with D-galactosamine

Compound ST1238 significantly reduces the lethality with both temporal treatment protocols adopted ($p < 0.001$ and $p < 0.01$) (Tables 2 and 3), whereas compounds ST 1274 and ST 1275 give rise to non-significant percentage increases in survival (20%) only with the pre- and post-challenge administration protocol (Table 2).

Tab. 2 Effect of ST 1238, ST1274 and ST 1275 i.v. administration on the lethality induced by injection of *E. coli* LPS in mice sensitised with D-galactosamine. Pre-/post-challenge treatment schedule (-30 and +5 min).

Treatment (dose)	Dead/Total	Survival increase ^a (%)	P ^b
LPS+D-GalN control	25/29	-	-
ST 626 (6 mg/kg, i.v.)	21/28	+11	ns
LPS+D-GalN control	17/20	-	-
ST 1238 (18 mg/kg, i.v.)	5/20	+60	<0.001
LPS+D-GalN control	7/10	-	-
ST 1274 (5.5 mg/kg, i.v.)	5/10	+20	ns
LPS+D-GalN control	7/10	-	-
ST 1275 (4 mg/kg, i.v.)	5/10	+20	ns

a = Percentage increase in survival of treated animals compared to control.

b = Statistical significance evaluated by one-tailed Fisher's exact test.

Tab. 3 Effect of ST 1238 i.v. administration on the lethality induced by injection of *E. coli* LPS in mice sensitised with D-galactosamine. Post-challenge only treatment schedule (+5 and +30 min).

5

Treatment (dose)	Dead/Total	Survival increase ^a (%)	P ^b
LPS+D-GalN control	16/20	—	—
ST 1238 (18 mg/kg, i.v.)	7/19	+44	<0.01

a = Percentage increase in survival of treated animals compared to control.

b = Statistical significance evaluated by one-tailed Fisher's exact test.

10 **Lethality induced by SEB (*Staphylococcus aureus*) in mice sensitised with D-galactosamine**

With this experimental model all the compounds reduce the lethality in comparison with controls (70%-90%) when administered 30 min before and 5 min after the challenge (Table 4). ST 1238 still maintains an extremely significant protective effect in the post-challenge only treatment schedule ($p < 0.001$) (Table 5).

Tab. 4 Effect of ST 1238, ST1274 and ST 1275 i.v. administration on the lethality induced by injection of LPS from SEB enterotoxin in mice sensitised with D-galactosamine.

Pre- and post-challenge treatment schedule (-30 and +5 min).

Treatment (dose)	Dead/Total	Survival increase ^a (%)	P ^b
SEB+D-GalN control	15/20	-	-
ST 1238 (18 mg/kg, i.v.)	1/20	+70	<0.001
SEB+D-GalN control	9/10	-	-
ST 1274 (5.5 mg/kg, i.v.)	0/10	+90	<0.001
SEB+D-GalN control	9/10	-	-
ST 1275 (4 mg/kg, i.v.)	1/10	+80	<0.01

a = Percentage increase in survival of treated animals compared to control.

b = Statistical significance evaluated by one-tailed Fisher's exact test.

Tab. 5 Effect of ST 1238 i.v. administration on the lethality induced by injection of LPS from SEB enterotoxin in mice sensitised with D-galactosamine.

Post-challenge only treatment schedule (+5 and +30 min).

5

Treatment (dose)	Dead/Total	Survival increase ^a (%)	P ^b
SEB+D-GalN control	18/20	—	—
ST 1238 (18 mg/kg, i.v.)	4/20	+70	<0.001

a = Percentage increase in survival of treated animals compared to LPS control.

b = Statistical significance evaluated by one-tailed Fisher's exact test.

10

EVALUATION OF THE EFFECT OF ST 1238 ON SERUM TNF (TUMOR NECROSIS FACTOR) LEVELS INDUCED BY LPS IN RAT BLOOD CULTURE

Cultures of whole blood cells stimulated by LPS were
15 utilised as an experimental model. This model, albeit with certain
limitations, mimics the physiopathological aspects of
endotoxaemia, a syndrome in which gram-negative bacteria
release lipopoly-saccharide into the blood-stream which thus
comes into contact with the immune system cells.

20 In fact, this model has recently been adopted for the
evaluation of potential inhibitors of the release of TNF and IL-1
(GC Rice et al., *Shock*, 4:254-266, 1994. AJH Gearing et al.,
Nature, 370:555-557, 1994. K Tschaikowsky, *Biochim. Biophys.*

Acta, **1222**:113-121, 1994. A Haziot et al, *J. Immunol.*, **152**:5868-5876, 1994).

Male Wistar rats (C. River) weighing about 175-200 g were utilised.

5 The animals, housed in cages at $22 \pm 2^\circ\text{C}$ and $50 \pm 15\%$ relative humidity with 12 h of light (7 am - 7 pm), had unrestricted access to food and drinking water.

The compound tested was ST 1238.

The endotoxin utilised was: LPS from *Salmonella typhosa*
10 batch 81H4018 (Sigma).

Treatment of blood samples

Heparinised blood samples, 0.450 mL/vials, were taken from Wistar rats sacrificed by decapitation.

Volumes of 0.025 mL (solution 20x) of the test compounds
15 (final concentration of 0.050 mM) dissolved in sterile saline were added to the vials containing the blood samples.

0.025 mL (sol 20x) of *Salmonella typhosa* LPS (final concentration in LPS equal to $1 \mu\text{g/mL}$) were added to the samples incubated for 1 h at 37°C in a humidified atmosphere with 5%
20 CO_2 .

The samples were incubated in the same conditions for 4 h and then centrifuged for 5 min at 10,000 rpm and the supernatant was stored at -80°C pending TNF assay.

TNF biological activity was determined in RPMI medium
5 containing 1% FCS.

TNF biological assay

For the TNF assay serial dilutions of the samples (50 µL) containing TNF were made directly into Primaria 96-well microtiter plates; actinomycin D-mannitol (50 µL) at a final concentration
10 of 4 µg/mL, prepared in RPMI medium added with 1% FCS, was added to the wells. This inhibitor enhances the cells sensitivity to TNF.

100 µL of a suspension (standardised at 4×10^5 cells/mL) of L929 (murine fibrosarcoma sensitive to the toxic action of TNF) were
15 dispensed into each well. Appropriate controls, i.e. the actinomycin-D control (cells + actinomycin-D but without TNF) and the cell control (cells + culture medium alone) were also prepared.

After further incubation for 18 h at 37°C with 5% CO₂, the
20 cells were stained with a freshly prepared solution of 1 mg/mL XTT (sodium 3'-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-meth-oxy-6-nitro)benzene-sulphonic acid hydrate) and 125 µM

PMS (phenazine methosulphate) according to the method described here below.

The XTT is dissolved (1 mg/mL) in RPMI medium at 60°C.

The PMS mother solution 100 mM (stable for about 20 days
5 at +4°C in the dark) is prepared by dissolving the PMS in PBS followed by brief sonication so as to fully dissolve the PMS. The 100 mM PMS solution is then diluted 1:800 in XTT, obtaining a final concentration of 125 µM in PMS and 1mg/mL in XTT. The staining mixture must be filtered prior to use.

10 Cells were stained by adding 50 µL/well of the XTT-PMS staining solution, obtaining a final volume of 250 µL/well with final concentrations of 0.2 mg/mL in XTT and 25 µM in PMS, respectively. A "blank" was also prepared in wells containing 200 µL of culture medium + 50 µL of XTT-PMS solution.

15 The microtiter plates are incubated for 2-2.5 h at 37°C with 5% CO₂ (total incubation time = about 20 h).

The absorbance values of each sample were measured with a microtiter plate reader at a reading wavelength of 450 nm and a reference wavelength of 620 nm (the microtiter plate reader was
20 programmed to deduct the value obtained for the "blank" from the sample value).

The TNF titre was calculated using the following method.

By definition, 1 unit of biological activity is given by the semimaximal value (= 50%) of the actinomycin-D absorbance.

Sample dilutions give rise to an absorbance value curve whose linear portion is described by the equation $y = ax + b$.

5 After inserting the a and b values (obtained from the linear regression analysis done by the computer) and after substituting the semimaximal absorbance value (corresponding to 1 biological unit) of the actinomycin-D control for y, the equation is solved for x, which represents the reciprocal of the sample dilutions.

10 The value obtained gives the TNF titre in U/mL.

Data were analysed statistically using the two-tailed Student's *t* test.

RESULTS

The results obtained (Table 6) show that compound ST 1238
15 reduces (39%) TNF production by rat blood cultures stimulated with LPS.

Tab. 6 Effect of ST 1238 on TNF production induced in rat blood cultures (n = 5) stimulated with *S. typhosa* LPS (1 µg/mL). The compounds were tested at a concentration of 50 µM. The experimental conditions are those described in Materials and Methods.

Treatment	TNF (mean % values)	Stand. Dev.	P*
LPS control	100	0	-
LPS+ST 1238	61	25	<0.01

*Statistical significance evaluated by two-tailed Student's *t* test

10 **EVALUATION OF THE EFFECT OF ST 1238 ON SERUM TNF LEVELS IN TWO MURINE SHOCK MODELS.**

Male BALB/c mice (C. River), aged approx. 6 weeks were utilised (10 animals per experimental group).

The animals, housed in cages at 22 ± 2°C and 50 ± 15% relative humidity with 12 h of light (7 am - 7 pm) and 12 h of darkness (7 pm - 7 am), had unrestricted access to food and drinking water.

The compound tested was ST 1238.

The substances utilised were: LPS (from *E. coli* serotype O26:B6, batch 73570 JB (Difco), SEB (*Staphylococcus aureus*)

batch 144H4024 (Sigma), D-galactosamine batch 031EE002485 (Merck).

Lethality induced by *E. coli* LPS in mice sensitised with D-galactosamine

5 The experimental conditions were exactly the same as those previously described.

Lethality induced by SEB (*Staphylococcus aureus*) in mice sensitised with D-galactosamine

10 The experimental conditions were exactly the same as those previously described.

Blood samples

In both experimental models, blood samples were taken 90 min after the challenge (peak serum TNF level).

15 Ether-anaesthetised mice were bled by retro-orbital sinus puncture.

Blood samples were incubated at room temperature for 2 h and the serum thus obtained was centrifuged for 20 min at 3000 rpm and stored at -80°C pending TNF assay.

TNF biological assay

20 TNF biological activity was determined in RPMI medium containing 1% FCS.

50 μ L/well of serial dilutions of samples containing TNF were added directly to the Primaria microtiter plates.

The experimental conditions utilised were the same as those previously described.

5 Data were analysed statistically using the one-tailed Student's *t* test.

RESULTS

Lethality induced by *E. coli* LPS in mice sensitised with D-galactosamine

10 The results obtained in this experimental model are reported in Table 7. Compound ST 1238 significantly reduces TNF levels induced by *E. coli* LPS with both treatment schedules (pre-/post- and post-challenge only; $p < 0.008$ and $p < 0.0001$, respectively).

15

20

Tab. 7 Effect of ST 1238, 18 mg/kg, i.v. administration on TNF production by injection of *E. coli* LPS in mice sensitised with D-galactosamine.

Pre- and post-challenge treatment schedule (-30 and +5 min) and post-challenge only treatment schedule (+5 and +30 min).

Treatment	-30/+5 min schedule			+5/+30 min shedule		
	TNF (U/mL)			TNF (U/mL)		
	Mean	S.D.	P	Mean	S.D.	P
LPS control*	154.2	41.0	-			
ST 626 (6 mg/kg, i.v.)	35.0	10.0	<0.01			
LPS +D-GalN control	13.6	4.7	-	18.1	1.8	-
ST 1238	0.4	0.2	0.008	2.2	0.6	0.0001

* Experiment conducted with *Salmonella typhosa* LPS.

10 **Lethality induced by enterotoxin SEB in mice sensitised with D-galactosamine**

The results obtained (Table 8) with this experimental model of TNF production induced by LPS from SEB enterotoxin in animals sensitised with D-galactosamine show that compound ST 1238 significantly reduces TNF production both with the pre-
 15 /post-challenge schedule ($p < 0.0001$) and with the post-challenge only schedule ($p < 0.0002$).

Tab. 8 Effect of ST 1238, 18 mg/kg, i.v. administration on TNF production induced by LPS from SEB enterotoxin in mice sensitised with D-galactosamine.

Pre- and post-challenge (-30 and +5 min) and post-challenge only treatment schedule (+5 and +30 min).

Treatment	-30/+5 min schedule			+5/+30 min schedule		
	TNF (U/mL)			TNF (U/mL)		
	Mean	S.D.	P	mean	S.D.	P
SEB +D-GalN control	240.9	49.4	-	240.9	49.4	-
ST 1238	6.2	3.0	0.0001	27.0	3.9	0.0002

**EVALUATION OF THE EFFECT OF ST 1238 ON SERUM
INTERLEUKIN-1 BETA (IL-1 β), INTERLEUKIN-6 (IL-6) AND
INTERFERON-GAMMA (IFN- γ) INDUCED BY ENTEROTOXIN
SEB, IN MICE**

Male BALB/c mice (C. River), aged approx. 6 weeks were utilised (10 animals per experimental group).

The animals, housed in cages at $22 \pm 2^\circ\text{C}$ and $50 \pm 15\%$ relative humidity with 12 h of light (7 am - 7 pm) and 12 h of darkness (7 pm - 7 am), had unrestricted access to food and drinking water.

The compound tested was ST1238.

The substances utilised were LPS from SEB (*Staphylococcus aureus*), batch 144H4024 (Sigma) and D-galactosamine batch 031EE002485 (Merck).

Lethality was induced by *S. aureus* SEB in mice sensitised
5 with D-galactosamine.

The experimental conditions were exactly the same as those previously described.

Blood samples

Blood samples were taken 2 h post-challenge for IL-6; 4 h
10 post-challenge for IL-1 β and 6 h post-challenge for IFN-g.

Ether-anaesthetised mice were bled by retro-orbital sinus puncture. Blood samples were incubated at room temperature for 2 h and the serum thus obtained was centrifuged for 20 min at 3000 rpm and stored at -80°C until assayed.

15 Biological tests

Biological tests were performed according to the procedures indicated in the respective assay kits utilised:

- Mouse IL-1 β Immunoassay (MLB00, R&D Systems)
- Mouse IL-6 EIA Kit (8-6706, PerSeptive Diagnostics)
- 20 -Mouse IFN- γ EIA Kit (8-6716, PerSeptive Diagnostics).

Data were analysed statistically using the one-tailed Student's *t* test.

RESULTS

Compound ST 1238 significantly reduces the production of the inflammatory cytokines assayed ($p < 0.001$ for IL-1 β ; 0.0001 for IL-6; 0.01 for IFN- γ); the results obtained are reported in Table 9.


Tab. 9. Effect of ST 1238, 19 mg/kg, i.v. administration on serum levels of IL-1 β , IL-6 and IFN- γ in model of intoxication with LPS from *S. aureus* SEB in mice sensitised with D-galactosamine

Pre- and post-challenge treatment schedule (-30 and +5 min).

Treatment	IL-1 β (pg/mL)			IL-6 (pg/mL)			IFN- γ (pg/mL)		
	Mean	s.e.	P	Mean	s.e.	P	Mean	s.e.	P
SEB + D- galactosamin e control	18	4	-	3493	558	-	40	3	-
ST 1238	0.9	0.5	0.001	599	163	0.0001	25	4	0.01


CLAIMS

1. 2-Aminotetralines having formula (I)



(I)

or their pharmacologically acceptable salts having formula (II)



(II)

wherein:

R and R₁, are independently, halogen; hydroxy; C1-C4 alkoxy, optionally substituted in position ω with groups OH, NH₂,

AMENDED SHEET

./.

NR₃R₄, wherein R₃ and R₄ are independently H, C1-C4 alkyl, unsubstituted or substituted in position ω with groups OH, NH₂; C1-C4 alkancyl; C1-C4 alkyl; carbamoyl; carbamoyloxy; amino; amino substituted NR₃R₄, where R₃ and R₄ have the aforesaid meanings;

R₂ is hydrogen; halogen; hydroxy; methoxy, with the proviso that the case is excluded in which the 2-aminotetraline is a raceme in which (a) R=R₁=CH₃O; OH; R₂=H; or (b) R=F; R₁=CH₃O; OH; R₂=H; and

X⁻ is the monovalent anion of a pharmacologically acceptable acid.

2. Compound according to claim 1, wherein the monovalent anion of a pharmacologically acceptable acid is selected from chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

3. A compound according to claim 1 which is selected from:

S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride

(ST 1237);

R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride

(ST 1238);

AMENDED SHEET

./.

(R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride

(ST 1269);

(R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride

(ST 1275);

(R,S)-2-amino-7-fluoro-6-hydroxytetraline hydrochloride

(ST 1267);

(R,S)-7-acetyl-2-amino-6-methyltetraline hydrochloride

(ST 1274);

(R,S)-2-amino-7-fluoro-6-methoxytetraline hydrochloride

(ST 1262).

4. An orally or parenterally administrable pharmaceutical composition containing a compound of formula I or II and a pharmaceutically acceptable carrier and/or diluent.
5. An orally or parenterally administrable pharmaceutical composition for the prevention and therapeutical treatment of inflammatory and/or autoimmune pathologies induced by inflammatory cytokines, and which comprises as active ingredient a compound according to claim 1, 2 or 3 and a pharmacologically acceptable excipient.
6. Composition according to claim 5, for the prophylactic and the therapeutical treatment of septic shock.

AMENDED SHEET

./.

7. Composition according to claim 5, for preparing a medicament for the therapeutic treatment of rheumatoid arthritis, pancreatitis, inflammatory bowel disease, systemic lupus erythematosus, glomerulonephritis and encephalomyelitis.

NOTED SHEET

./.